The strong trader consensus behind the 95.5% implied probability of no hantavirus vaccine in 2026 stems from the fact that all active candidates remain in preclinical or early Phase 1 stages, with no programs having completed the multi-year sequence of human efficacy trials, manufacturing validation, and regulatory review required for licensure. Promising 2026 data, such as single-dose mRNA constructs demonstrating full protection against Andes virus in hamster models, confirm immunogenicity in animals but have yet to generate human safety or efficacy results. Historical precedents show even accelerated vaccine pathways exceed 12–18 months from initial human dosing to approval, and current surveillance from agencies like the CDC and WHO indicates no emergency-use pathways are positioned for 2026 resolution.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% 確率
$135,595 Vol.
$135,595 Vol.
2026/12/31
5% 確率
$135,595 Vol.
$135,595 Vol.
2026/12/31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong trader consensus behind the 95.5% implied probability of no hantavirus vaccine in 2026 stems from the fact that all active candidates remain in preclinical or early Phase 1 stages, with no programs having completed the multi-year sequence of human efficacy trials, manufacturing validation, and regulatory review required for licensure. Promising 2026 data, such as single-dose mRNA constructs demonstrating full protection against Andes virus in hamster models, confirm immunogenicity in animals but have yet to generate human safety or efficacy results. Historical precedents show even accelerated vaccine pathways exceed 12–18 months from initial human dosing to approval, and current surveillance from agencies like the CDC and WHO indicates no emergency-use pathways are positioned for 2026 resolution.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
マーケット開始日： May 4, 2026, 10:39 AM ET
音量
$135,595終了日
2027/01/01マーケット開始日
May 4, 2026, 10:39 AM ETリゾルバー
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong trader consensus behind the 95.5% implied probability of no hantavirus vaccine in 2026 stems from the fact that all active candidates remain in preclinical or early Phase 1 stages, with no programs having completed the multi-year sequence of human efficacy trials, manufacturing validation, and regulatory review required for licensure. Promising 2026 data, such as single-dose mRNA constructs demonstrating full protection against Andes virus in hamster models, confirm immunogenicity in animals but have yet to generate human safety or efficacy results. Historical precedents show even accelerated vaccine pathways exceed 12–18 months from initial human dosing to approval, and current surveillance from agencies like the CDC and WHO indicates no emergency-use pathways are positioned for 2026 resolution.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
音量
$135,595終了日
2027/01/01マーケット開始日
May 4, 2026, 10:39 AM ETリゾルバー
0x65070BE91...The strong trader consensus behind the 95.5% implied probability of no hantavirus vaccine in 2026 stems from the fact that all active candidates remain in preclinical or early Phase 1 stages, with no programs having completed the multi-year sequence of human efficacy trials, manufacturing validation, and regulatory review required for licensure. Promising 2026 data, such as single-dose mRNA constructs demonstrating full protection against Andes virus in hamster models, confirm immunogenicity in animals but have yet to generate human safety or efficacy results. Historical precedents show even accelerated vaccine pathways exceed 12–18 months from initial human dosing to approval, and current surveillance from agencies like the CDC and WHO indicates no emergency-use pathways are positioned for 2026 resolution.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問